University of Florida Research Foundation Inc

Margaret Mary Fettis

Benjamin George Keselowsky

Gregory Allan Hudalla, Ii

Antonietta Restuccia

Shaheen Farhadi

Evelyn R Bracho-Sanchez

Sabrina Freeman

Gregory Hudalla

Provided herein are targeted effector fusion proteins, complexes thereof, and uses thereof. The targeted effector fusion proteins can include an effector protein that can be linked to a targeting moiety. Monomer targeted effector fusion proteins can form homogeneous or heterogeneous complexes. The targeted effector fusion proteins and complexes thereof can be formulated as pharmaceutical formulations. The targeted effector fusion proteins, complexes thereof, and formulations thereof can be administered to a subject in need thereof.

Targeted effector proteins and uses thereof

Described herein are modified gal1 monomers that can contain one or more mutated cysteines and/or can be pegylated. Also described herein are modified gal1 dimers, trimers, and tetramers that can contain one or more modified gal1 monomers as described herein. Also described herein are pharmaceutical formulations containing a modified gal1 monomer, dimer, trimer, and/or tetramer. Also described herein are methods of making the modified gal1 polypeptides and complexes thereof. Also described herein are methods of using the modified gal1 polypeptides and complexes thereof.

Modified gal-1 proteins and uses thereof

Growing community of inventors

Gainesville, FL, United States of America

Margaret Mary Fettis